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Executive Summary
This Expert Consensus document updates the initial docu-
ment published in 1996.
In Summary
● Stenting, particularly with high pressure postdeployment
balloon inflation and adjunctive therapy with acetyl sali-
cylic acid (ASA) and ticlopidine have been proven to
reduce angiographic and clinical restenosis compared to
conventional dilatation. In several areas, widespread
clinical practice patterns have occurred in advance of
rigid controlled scientific data. The consensus recommen-
dations are based upon scientifically controlled trials,
single and multicenter experience and clinical practice.
● In selected patients with focal stenosis in native coronary
arteries, stent implantation with high pressure postde-
ployment inflation and adjunctive therapy with ASA and
ticlopidine have been definitively proven to reduce an-
giographic and clinical restenosis compared to conven-
tional dilatation.
● Stenting can improve the longer-term outcome of se-
lected patients being treated for chronic total occlusion
and can result in improved restenosis rates in selected
patients.
● Vein graft disease remains a significant problem because
of the often diffuse nature of the process and the
underlying severe coronary artery disease. In selected
patients and lesions, stents have resulted in improved
initial success rates and larger acute angiographic gain.
Restenosis rates and longer-term morbidity remain in-
creased.
● Stenting is a promising approach to optimize the results
of catheter-based therapy and to treat complications of
primary angioplasty. Whether stenting should be used
only to treat suboptimal results or should be recom-
mended as a primary therapy is still under study. Ran-
domized trials within the next 2 years should resolve
these issues.
● Stenting results in improved outcome in selected patients
with restenosis following conventional percutaneous
transluminal coronary angioplasty (PTCA). In contrast,
the role of stenting for instent restenosis is uncertain. It
may be useful for focal stenoses, and when conventional
dilatation does not result in an excellent angiographic
outcome. For diffuse instent restenosis, there are insuf-
ficient data upon which to base a recommendation.
● The currently available data on treatment of small vessels
indicate that it is safe but that it does not result in
improved longer-term outcome compared with conven-
tional PTCA provided that dilatation gave a satisfactory
initial result. Stents remain useful in this setting if the
results of conventional PTCA are suboptimal with per-
sistent significant residual obstruction.
● The treatment of long lesions or diffuse disease remains
problematic. Long stents or multiple stents may play an
important role when the result of conventional dilatation
is suboptimal. Restenosis rates appear to be increased
but may be improved compared with conventional
PTCA.
● Intravascular ultrasound provides substantial informa-
tion as an adjunctive approach to guide stent placement.
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Accumulating data indicate that it can be used to opti-
mize early and longer-term outcome in selected patients.
I. Preamble
Topics chosen for coverage by Expert Consensus docu-
ments are designated because the evidence base and experi-
ence with the technology or clinical practice are not sufficiently
well developed to be evaluated by the formal American
College of Cardiology/American Heart Association (ACC/
AHA) Practice Guidelines process. The Expert Consensus
document represents the ACC’s best attempt to guide clinical
practice in areas where rigorous evidence is not fully mature.
Such documents require frequent revision. Ever since the
initial Expert Consensus on Coronary Stents (1), the knowl-
edge base has increased significantly. In many institutions,
stents are the most commonly performed interventional cardi-
ology procedure (2).
II. Introduction
More than 500,000 Americans and 1,000,000 patients
worldwide undergo a nonsurgical coronary artery interven-
tional procedure yearly. In many laboratories, stents are now
used in over 50% of cases (2). The first Expert Consensus
document (3) included two completed trials using a single type
of stent (Palmaz-Schatz™) (3–5) and the approval process that
culminated in Food and Drug Administration (FDA) approval
of two stents: 1) the Gianturco-Roubin™ (G-R) approval for
acute or threatened closure during coronary intervention (6–9)
and 2) the Palmaz-Schatz™ (P-S) for selected patients eligible
for balloon angioplasty with discrete, de novo native coronary
artery lesions in large-millimeter vessels.
Only a small percentage of patients undergoing percutane-
ous coronary revascularization are candidates for stents based
upon the initial FDA-approved selection criteria. The greatly
expanded practice of stenting for other indications was the
result of widespread operator experience, significant changes
in implantation procedures with high pressure balloon infla-
tion, changes in adjunctive medications including ASA and
ticlopidine, documentation of continued improved early and
long-term results, and continued insights from complementary
techniques such as Intravascular ultrasound (IVUS) and cor-
onary flow or gradient measurements.
Description and Analysis of Technology
Basic Technology
There are two broad groups of stent devices: 1) balloon
expandable and 2) self-expanding. Within these groups, there
is substantial variability, which has led to approximately 500
issued stent-related patents using a variety of delivery systems,
metals, architecture, length and design. In addition, new stent
designs allow delivery of drugs, radiation or other biological
material to help further reduce stent thrombosis and possibly
restenosis.
Balloon Expandable
At the time of the initial consensus document, there were
only two FDA-approved stents (i.e., G-R and P-S) both of
which are balloon expandable. During 1998, it is anticipated
that approximately nine balloon-expandable stents will be
available in the United States. The structure of balloon-
expandable stents ranges from metallic coils arranged in
different patterns to slotted tubular designs to hybrids. Device
performance, deliverability, flexibility, radial strength, accessi-
bility to side branches, and radio-opacity vary. The method of
delivery also varies (i.e., sheathed stents vs. bare metal stents).
Clinically important differences in performance parameters
between different stents are difficult to assess.
Self-Expanding
This group includes the initial stent used in coronary
arteries, the Wallstent (Medinvent-Schneider, Lausanne, Swit-
zerland) (10–12). Although this initial stent has been modified,
its fundamental properties remain unchanged (13). There are
also other newer devices in this group with some unique
metals. Nitinol, for example, can expand to a predetermined
size. This feature may foster continued local arterial enlarge-
ment over time (14). Self-expanding devices require some type
of sheath; this may limit some devices because of the added
bulk and external diameter of the sheath.
Stents as Local Delivery Devices
Various local drug delivery devices are currently available.
These have not used a stent platform. At the present time,
heparin has been used to coat stents. In the future, other
coatings will be available that have the potential to improve
early and longer-term outcome.
Method of Data Collection
The rapid evolution of stent design, deployment ap-
proaches, and adjunctive therapy have led to changes in clinical
practice patterns that precede rigidly controlled supporting
scientific data. This Expert Consensus document uses data
from both randomized clinical trials and observational studies.
Recently completed but not yet published clinical trials are
also included. Multicenter randomized trials were given more
weight in recommendations than were single-center observa-
tional experiences.
Currently, several randomized trials are comparing one
stent versus another (15), which will allow evaluation of some
aspects of device performance (e.g., procedural success, need
for device crossover and clinical outcome). These trials are
designed as equivalency trials (16–18) rather than the tradi-
tional superiority trial design used in STRESS (4) and
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BENESTENT (5). As a greater variety of stent designs be-
comes available, there will be increasing emphasis on matching
the specific device to the angiographic anatomy. This will
become increasingly important as stents are used in less ideal
lesions (e.g., calcified small vessels, ostial stenoses, vein graft
disease, and long lesions).
Potential Indications for Stenting
Potential indications for stents include 1) prevention of
restenosis, 2) optimizing the initial result of treatment in
lesions felt to be high risk because of adverse angiographic
characteristics, 3) optimizing the result of conventional PTCA,
and 4) treatment of acute or threatened closure.
Prevention of Restenosis
In the STRESS-I (4) and BENESTENT-I (5) trials, reduc-
tion in restenosis was the result of achieving a larger initial
lesion minimal lumen diameter. Although stenting resulted in
more late loss of diameter than did PTCA, the loss was more
than compensated by the greater initial acute gain.
The subsequent randomized BENESTENT-II trial of stent
implantation using current deployment techniques versus con-
ventional PTCA included 827 patients with selection criteria
similar to that in BENESTENT-I (19,20). Angiographic resten-
osis rates were significantly less in patients randomized to the
heparin-coated stent (17.0% vs. 31.0%), a reduction of 45%
(p , 0.01). Angiographic restenosis rates were similar to the
low rates seen in BENESTENT-II pilot (21) and slightly less
than in BENESTENT-I. The results of conventional dilatation
were also markedly improved compared to historical controls.
Assessment of stents for reducing restenosis is, in part,
dependent on the definition of restenosis. Although angio-
graphic documentation of restenosis is an objective end point,
from the patient’s standpoint, clinical restenosis is more im-
portant. Assessment of clinical restenosis is less rigorous,
because it can be affected by the presence of untreated lesions,
medication use, the disparity between symptoms and angio-
graphic findings, and the lack of patient and physician blinding.
Target lesion or target vessel revascularization (TLR) has been
used as a surrogate for angiographic restenosis, although with
multiple lesions that may be problematic. In BENESTENT-I,
there was a significant reduction in need for repeat revascu-
larization (10.0% vs. 20.6%, p 5 .001) at 1 year (21). In
BENESTENT-II, the magnitude of the benefit was somewhat
less. The TLR in the stented group was 13%, compared to
15.7% for the PTCA group. In the Multicenter Ultrasound
Stenting in Coronaries Study (MUSIC) (22), 161 patients with
stable angina and a de novo native coronary artery lesion were
treated with a second-generation P-S stent using IVUS guid-
ance. When predetermined IVUS criteria were met, patients
were treated only with ASA. Subacute stent thrombosis was
documented in two patients (1.3%). Repeat angiography was
performed at 6 months in 140 patients (89%). Restenosis
(diameter stenosis .50% at follow-up) was documented in
only 11 patients (8%), and target lesion revascularization was
required in only 7 patients (4.5%).
It must be kept in mind that when conventional dilatation
results in an excellent angiographic result with a residual
stenosis ,20% or when normal physiologic flow reserve has
been restored, restenosis rates have also been found to be
decreased compared with historical cohorts of patients under-
going PTCA.
Longer-term follow-up data for stents is now available.
Kimura et al. (23) performed serial angiography at 6, 12 and 36
months after P-S stent placement in 143 patients. They con-
firmed that the major loss in minimum lumen diameter (MLD)
occurred within the first 6 months: 2.55 6 0.46 mm immedi-
ately following implantation to 1.94 6 0.48 at 6 months, 1.95 6
0.46 at 1 year and 2.09 6 0.48 at 3 years (p , 0.001).
Although much of the published benefit in restenosis
reduction with stent implantation has been confined to analysis
of P-S stents, a current group of randomized trials indicates
that restenosis rates with newer-generation devices (e.g., ACS
Multilink™, AVE, and Sci Med NIR™ stents are similar). An
exception to this appears to be the Gianturco-Roubin (G-R)
II™ stent, which has higher restenosis rates (24) that may
relate to stent design or implantation techniques.
Summary
In selected patients with focal stenosis in native coronary
arteries, stent implantation with high pressure postdeployment
inflation and adjunctive therapy with ASA and ticlopidine have
been definitively proven to reduce angiographic and clinical
restenosis compared to conventional dilatation.
Issues in Evaluating Stent Restenosis Trials
Current stent trials utilize clinical events including TLR as
primary end points with an angiographic or IVUS substudy to
examine mechanisms. An important consideration in use of
TLR is that after routine follow-up angiography, there is often
a “flurry” of additional revascularization procedures. In the
BENESTENT-II trial of conventional PTCA versus stent
implantation, one-half of each group had angiographic follow-
up, and one-half had clinical follow-up alone (25). In those
patients undergoing angiographic follow-up, the incidence of
repeat TLR was significantly greater (14.4% vs. 9.1%). Thus,
the results of follow-up angiography may affect subsequent
clinical decisions irrespective of patient symptoms. The rates of
revascularization are higher in studies with mandated routine
angiographic follow-up.
Another important issue is that the randomized trials of
stent implantation compared with conventional PTCA involve
highly selected patient and lesion subsets. Recent data indicate
that lesions and patients meeting STRESS/BENESTENT cri-
teria account for only about 25% of current stent practice. In
the remainder of the patients and lesions, data are lacking as to
the impact of stenting on reduction in restenosis. Restenosis
rates may or may not be superior to conventional PTCA, but
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they are likely to be higher than those in STRESS/
BENESTENT ideal lesions. Many of these other lesion/patient
subsets are currently being studies in randomized trials.
Chronic Total Occlusion
The treatment of chronic total occlusion (CTO) with con-
ventional PTCA has been limited by the inability to cross the
occlusion, increased restenosis rates, the size of the distal
vessel, and viability of myocardium supplied by the occluded
vessel. If the vessel is small and supplies only infarcted
myocardium, there is no need for revascularization. In the
multicenter trial MERCATOR (26), patients with successful
dilatation of a CTO had a 6-month restenosis rate of 49%. One
of the most important findings has been that, after successful
PTCA of a CTO, the artery reoccludes in approximately 20%
of patients. Stenting may affect this favorably.
There are several small reports of PTCA versus stenting for
CTO. Sirnes et al. (27) evaluated the outcome of 117 patients
with chronic total occlusion treated with either PTCA or a P-S
stent. At the time of follow-up, there were significant differ-
ences in restenosis (32% vs. 74%, p , 0.001), target lesion
revascularization (22% vs. 42%, p 5 0.025), and freedom from
angina (57% vs. 24%, p , 0.001) favoring patients treated with
stents. In another study of 96 patients, Mori et al. (28) found a
restenosis rate of 28% in patients receiving stents compared to
57% of patients treated with PTCA alone (p 5 0.005). There
was also a significant decrease in repeat target lesion revascu-
larization in stented patients (p 5 0.05).
Summary
Stenting can improve the longer-term outcome of patients
being treated for chronic total occlusion and can result in
improved restenosis rates in selected patients.
Saphenous Vein Graft (SVG) Disease
Interventional treatment of SVG disease has increased the
risk of both acute complications and late restenosis. As out-
lined in the first consensus document, observational multi-
center data on both coronary P-S and biliary stent implantation
appeared to show improved initial success rates and better
longer-term outcome. In the most recent observational expe-
rience of 589 patients (29), the initial procedure success rate
was 98.8%. At a mean follow-up of 8.1 6 4.0 months,
angiographic restenosis was 30%. However, the incidence of
mortality was 5%, and 19.1% of patients had either death,
Q-wave infarction or had repeat bypass surgery.
The multicenter randomized trial SAVED (Saphenous
Vein Graft De Novo Study) (30) compared P-S stents to PTCA
in de novo lesions, which required no more than two stents. All
patients had angina and/or evidence for ischemia, preserved
left ventricular function, and no contraindications to anticoag-
ulation. The mean vein graft age was 10 years with a mean
diameter of 3.19 mm. Technical success (,50% stenosis by
quantitative coronary angiography [QCA] was 95% in the stent
group compared with 75% for PTCA (p , 0.0001). Postpro-
cedural MLD was 2.81 mm with the stent versus 2.16 mm (p ,
0.0001) with PTCA. Clinical success was 92% for a stent and
69% for PTCA (p , 0.0001). There was a trend toward fewer
non-Q-wave myocardial infarctions (MI) in stented patients (2
vs. 7 patients, p 5 0.01), whereas Q-wave MI, death or need for
bypass surgery occurred at similar rates in each group. At 6
months, late loss with stents was greater (1.04 mm vs. 0.68 mm,
p 5 0.01) but net gain remained significantly larger (0.87 mm
vs. 0.52 mm) (p 5 0.015). The major cardiac event rate (death,
MI, need for repeat revascularization) at 6 months was 26%
after stenting versus 38% for PTCA (p 5 0.05). However,
there was no difference in angiographic restenosis: 37% with
stents, 46% with PTCA (p 5 0.24).
The Palmaz Biliary stent, which has greater radial strength,
a larger expanded diameter, and variable length, has been
widely used for vein grafts. Single-center and multicenter
experiences have documented good initial success rates
(31,32), but higher follow-up mortality. Wong et al. (32)
reported a single-center experience of 188 biliary stents in 124
patients with 163 vein graft lesions. In 82.8% of patients, a
single stent was placed with angiographic success in 98.8% of
cases. Major complications (death, emergency coronary artery
bypass grafting [CABG], subacute thrombosis) occurred in
3.3% of patients and non-Q-wave infarction in 11%, and
vascular complications and vascular repair in 10.1% of pa-
tients. The vascular complications reflect intense antiplatelet/
anticoagulant regimens that were utilized at that time. During
a mean follow-up of 142 6 75 days in 115 patients, event-free
survival was 80%.
Summary
Vein graft disease remains a significant problem because of
the often diffuse nature of the process and the underlying
severe coronary artery disease. In selected patients and lesions,
stents have resulted in improved initial success rates and larger
acute angiographic gain. Restenosis rates and longer-term
morbidity remain increased compared to stenting in large
native coronary arteries.
Acute Myocardial Infarction
Multiple small observational studies of stents for acute
myocardial infarction (MI), either as a primary procedure or
for bailout after unsuccessful direct PTCA, appear promising.
In a prospective multicenter trial, Stone et al. (33) analyzed
312 patients treated with primary PTCA. Stenting was at-
tempted in 240 patients and was successful in 98% of patients,
with restoration of TIMI-3 (Thrombolysis in Myocardial In-
farction trial) flow in 96%. Patients treated with stents had
improved final diameter stenosis (12 6 16% vs. 33 6 14% for
PTCA) and by 30 days required fewer subsequent revascular-
ization procedures (3.4% vs. 12.5% for PTCA, p 5 0.003).
In-hospital mortality in stented patients was 0.8%, and 1.7%
had recurrent ischemia.
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These and other data provide the basis for the multiple
current randomized trials of PTCA versus primary stenting for
acute infarction (15). The FRESCO trial (34) randomized
patients treated for acute infarction in whom primary angio-
plasty had already achieved an excellent result (defined as
either a residual stenosis of ,30% and TIMI-3 flow) to either
adjunctive stenting or no stenting. One hundred forty-six
patients were randomized. Rates of recurrent ischemia, resten-
osis, and reocclusion were significantly improved in the stented
patients. This improvement was maintained at 6 months.
Although incomplete angiographic follow-up was available, the
stented patients had a 12% incidence of restenosis or reocclu-
sion compared to 52% of the nonstented patients.
A second trial of acute infarction (ESCOBAR) (35) en-
rolled 204 patients randomized to either PTCA or stent. The
success rate was 96% and 98%, respectively. There was a
significant difference in the frequency of subacute closure and
recurrent myocardial infarction, with the stented patients
having improved outcome. Recurrent MI was seen in 2% in the
stent group versus 7% in the PTCA group.
The large Primary Angioplasty in Myocardial Infarction
Study Group (PAMI) Stent trial has recently been reported
that randomized 452 patients to stent implantation and 440 to
conventional PTCA. At 30 days, there was no statistically
significant difference in mortality (3.5% stent; 1.8% PTCA),
but there was a reduction in need for repeat target vessel
intervention (0.9% for stent vs. 3.5% for PTCA). Several other
trials including the 2000-patient Cadillac trial are currently
being performed (15).
Summary
Stenting is a promising approach to optimize the results of
catheter-based therapy for acute MI and to treat complications
of primary angioplasty. Whether stenting should be used only
to treat suboptimal results or should be recommended as a
primary therapy is still under study. Ongoing randomized trials
should resolve these issues.
Treatment of Restenotic Lesions
The restenosis rate after PTCA and other coronary inter-
ventional procedures is 30% to 50%. In all series, clinical
restenosis or restenosis requiring treatment is less frequent
than angiographic restenosis. The responsible mechanisms
include remodeling, neointimal hyperplasia, and recoil. Re-
stenosis following stenting usually results from neointimal
hyperplasia, although, occasionally it may be the result of
tissue prolapse or inadequate coverage of the initial lesion.
When restenosis occurs after PTCA, the predominant
mechanisms are recoil and remodeling, both of which respond
well to stent implantation. The importance of recoil after
conventional PTCA was evaluated by Rodriguez et al. (36),
who performed routine follow-up angiography at 24 hr after
successful balloon angioplasty in 191 consecutive patients.
Sixty (36%) had excessive lumen loss greater than 0.3 mm.
Patients were randomized to receive either standard medical
therapy or a GR stent. At a mean follow-up of 3.6 months,
follow-up angiography documented restenosis in 76% of the
medically treated patients compared to 21% of the stented
patients (p , 0.001).
Columbo et al. (37) reported on 125 patients treated with
stents for restenosis after PTCA. The acute success rate was
98%, with a late angiographic restenosis rate of 25% and
clinical restenosis of 17%. The REST trial (38) (stent vs. PTCA
restenosis trial) randomized 351 patients with restenosis to
either a P-S stent or PTCA. There was a significant decrease in
need for target vessel revascularization (10% in stented pa-
tients vs. 27% in PTCA patients, p 5 0.006) and angiographic
recurrent restenosis (18% stent vs. 32% PTCA).
Instent restenosis (39–44) occurs in three forms: 1) diffuse
neointimal hyperplasia throughout the stent; 2) discrete lesions
within the body of the stent, which may result from tissue
prolapse or initial inadequate coverage; and 3) margin resten-
osis, which is usually discrete and may result from a dissection
caused by high pressure PTCA at the time of implantation.
Both of the latter two types of instent restenosis respond well
to conventional dilatation (45). Many investigators favor de-
bulking of the neointimal tissue in diffuse instent restenosis,
although there is limited data on this approach (46,47).
Summary
Stenting results in improved outcome in selected patients,
with restenosis following conventional PTCA. In contrast, the
role of stenting for instent restenosis is uncertain. It might be
useful for focal stenoses, and when conventional dilatation
does not result in an excellent angiographic outcome. For
diffuse instent restenosis, there is insufficient data upon which
to base a summary.
Small Vessels
Although the early randomized stent trials by protocol
design required reference vessel diameter $3.0 mm, a signifi-
cant number of vessels when measured by quantitative angiog-
raphy were found to be ,3.0 mm (48). In STRESS-I and
BENESTENT-I, in vessels ,3.0 mm, the immediate results
were improved in patients treated with stents, but the benefit in
restenosis reduction was limited and did not reach statistical
significance. In a meta-analysis of BENESTENT and STRESS
I and II studies, in vessels ,2.6 mm and greater than .3.4 mm,
there was no advantage in either clinical events or restenosis of
stents versus conventional PTCA with an excellent angio-
graphic result (15). In BENESTENT for vessels ,3 mm, there
was no difference in the combined end point of death, infarc-
tion, coronary bypass or re-PTCA between PTCA (17.4) and
stent (18.5). Although one of the concerns with stenting of
small vessels has been the potential for an increase in subacute
closure, this does not appear to be the case. An increasing
number of observational studies in this group document safety
and early efficacy. A randomized trial is currently underway.
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Summary
The currently available data on treatment of small vessels
indicate that it is safe but that it does not result in improved
longer-term outcome compared with conventional PTCA pro-
vided that dilatation gives a satisfactory initial result. Stents
remain useful in this setting if the results of conventional
PTCA are suboptimal with persistent significant residual ob-
struction.
Long Lesions and Diffuse Disease
Long lesions or diffusely diseased vessels are often calcified,
and distal runoff may be compromised. Conventional PTCA is
associated with increased acute complications (i.e., dissection,
acute closure) and increased restenosis. Placement of multiple
stents has been associated with increased rates of stent throm-
bosis (49). With changes in implantation techniques, including
high pressure dilatation, aspirin/ticlopidine, intravascular ul-
trasound, and IIb/IIIa receptor inhibitors, overall complication
rates have decreased. These advances, combined with the
availability of longer, smaller and more flexible stents, make
stenting more attractive. Although there are a number of
observational series, there are no controlled trials. Kastrati et
al. (50) reported 1,084 patients with 1,399 stented lesions
undergoing follow-up angiography. The three factors associ-
ated with increased restenosis were placement of multiple
stents, diabetes mellitus, and minimal lumen diameter (MLD)
immediately after stent implantation. Although long lesions
(51) and diffuse disease subsets may have increased restenosis
rates with stenting, they may still be improved compared with
conventional PTCA. This area needs further study.
Summary
The treatment of long lesions or diffuse disease remains
problematic. Long stents or multiple stents may play an
important role when the result of conventional dilatation is
suboptimal. Restenosis rates appear to be increased but may
be improved compared with conventional PTCA.
Treatment of Acute or Threatened Closure
Ever since preparation of the initial Expert Consensus
document, there is increasing data on the importance of
treating acute or threatened closure with stent implantation
(5,7,8,50,52–54). The incidence of acute or threatened closure
has been decreasing in current interventional practice. In
STRESS the incidence of abrupt closure rate was 1.5% in
patients treated with PTCA. This may be the result of early
stent deployment when dissections are first identified but
before the onset of acute or threatened closure. In EPILOG,
BOAT, and BENESTENT-II, provisional stenting (i.e., stent-
ing to treat suboptimal results with PTCA or atherectomy) was
used in 14% of patients (55).
Summary
Stenting is the treatment of choice of either acute or
threatened closure complicating PTCA and for treatment of
dissection. The goal should be to restore full TIMI-3 flow.
Emergency surgery may still be required in some cases—for
example, a dissection involving the left main or significant
bifurcations, refractory thrombosis, loss of guide wire access,
or inability to deliver a stent to the target site.
Other Unfavorable Lesions
There are other lesion subsets for which there are only
observational reports but no randomized data.
Bifurcation Lesions
Treatment of bifurcation lesions is associated with in-
creased early complications including compromise of either
the branch vessel or the target lesion, and increased potential
for restenosis because of inadequate initial result. Stenting has
an additional potential problem in that it may impair access to
the side branch. Newer stent approaches including bifurcation
stents, T stents, and protective guide wires may improve
outcome, but further study is needed. Prior to stenting, the size
of the branch, target lesion, presence and severity of ostial
stenosis, and angle of the branch must be taken into account.
Ostial Lesions
Ostial lesions respond poorly to conventional PTCA, with
inadequate dilation and elastic recoil. In addition, a major
branch may arise from the ostium. Stents can be an excellent
treatment for elastic recoil. Whether debulking is also required
is uncertain. Stent implantation must be precise—if positioned
too proximally, the device may protrude into the aorta and
make repeat catheterization difficult, or may compromise a
branch vessel.
Left Main Coronary Artery Disease (LMCA)
Stenting of the LMCA is being performed relatively infre-
quently, primarily in patients who have had prior coronary
bypass surgery (56). Debulking is frequently performed with
rotational atherectomy because of calcification. Stenting can
result in improved initial and longer-term outcomes compared
with balloon angioplasty.
Stenting is also being performed in patients who have not
undergone prior CABG. The outcome in these patients de-
pends upon the baseline characteristics. In patients who are
excellent surgical candidates, the results may be superior to
those obtained in patients who are poor operative candidates.
No long-term comparison study with surgical results has been
performed.
Generalizability of Current Knowledge
Stents differ substantially in design and material. These
differences may affect outcomes. Current randomized trials
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may allow detection of differences between stents, and be-
tween lesions under treatment (57).
Which Patients/Lesions Should Be Stented?
Philosophies regarding which patients and/or lesions should
be treated with a stent as opposed to conventional PTCA still
differ substantially. In the United States, 40% to 50% of
angioplasty patients receive at least one stent. However, there
are operators who use them more often and others who use
them less. At one extreme is the position that every patient
undergoing dilatation should receive a stent if it can be placed.
With such an unrestricted strategy, stenting is performed
prophylactically. Inherent in this approach is the fact that some
stents would not have been necessary. This is important
because instent restenosis is more difficult to manage than
restenosis after conventional PTCA.
The other approach is provisional stenting. Randomized
trials and observational series have documented that when an
ideal result is achieved with conventional PTCA, measured
either with quatitative coronary angiography or with physio-
logic assessment, stenting is not required to achieve an excel-
lent longer-term result (58). With provisional stenting, the
operator chooses initial conventional dilatation equipment
estimated to achieve an excellent or ideal result with PTCA. If
such an excellent or ideal result is obtained with PTCA then
stenting is not performed. If results of PTCA are suboptimal,
stenting is performed.
The percentage of patients in which “ideal” PTCA result is
achieved is about 25% to 50%. These patients would avoid the
need for stenting. The cost-effectiveness of provisional stenting
has not yet been established.
Adjunctive Approaches: High Pressure
Deployment and Adjunctive Therapy
The major factors responsible for the dramatic increase in
stent implantation have been the changes in deployment
technique:
Stent deployment. During initial experience with stenting,
low pressure deployment was felt to be adequate. However,
IVUS examination documented that, with low pressure, al-
though the stent appeared to be fully deployed by angiography,
there was not full apposition to the arterial surface, creating a
risk for subacute closure. With this fundamental insight, inves-
tigators changed deployment techniques to incorporate a “high
pressure” approach, to expand the stent fully and appose it to
the vessel wall. Currently, balloons accommodate inflation
pressures as high as 25 atmospheres (atm). At the present time,
stents usually are dilated following initial deployment with a
higher pressure balloon to $12–16 atm. If the angiographic or
IVUS results are not satisfactory, then either higher pressure
or a larger balloon (e.g., an increase by 0.25 to 0.50 mm) or
both are used. Newer stent delivery systems incorporate high
pressure balloons so that the stent can be delivered, deployed
and dilated with relatively high pressure using the same
balloon.
The exact definition of high pressure inflation has yet to be
determined. The French Multicenter Registry (59) has re-
ported a consecutive, prospectively enrolled group of 2,900
patients utilizing high pressure stent deployment (mean of
12.4 6 3.05 atm) without IVUS guidance. A 1-month event-
free outcome was achieved in 97.1% of patients. Stent-related
cardiac events were subacute closure (1.8%), death (0.5%),
acute infarction (0.6%) and coronary bypass surgery (0.3%).
Whether these excellent results reflect the need to use only
lower pressure, patient selection, or operator experience is
unclear.
There is debate as to whether excessively high pressure and
stent oversizing may be deleterious. In some patients, high
pressure may cause margin dissection at the junction of the
stent with the adjacent artery. Short of performing routine
IVUS after each inflation, routine high pressure (.12–16 atm)
yields excellent results and is now relatively standard. Recently,
the Can Routine Ultrasound Influence Stent Expansion Study
(CRUISE) (60) has reported results. Two hundred and twenty-
nine patients had IVUS performed during stent implantation
to document final lumen; 270 patients had stent deployment
with IVUS guidance. Investigators found that average minimal
stent area was larger in the IVUS-guided limb as well as the
angiographic MLD posttreatment. This resulted in a reduction
in TLR (8.5% for IVUS guided vs. 15.3% p 5 0.019). This
study may change the utilization patterns of IVUS.
Pharmacotherapy. In the ISAR (61,62) trial, patients who
had successful P-S stent placement were randomized to either
aspirin plus ticlopidine or anticoagulant therapy with heparin,
warfarin and aspirin. At 30 days, the antiplatelet therapy group
had a significant reduction in the risk of infarction, need for a
repeat intervention, peripheral vascular events, and subacute
closure. Consequently, many operators in the United States
eliminated Coumadin in selected patients at low risk for stent
thrombosis (63). Heparin is given only during the procedure,
and access sheaths are removed as soon as the activated
clotting time (ACT) returns to approximately 160 s, which is
usually within 4 hr. Aspirin, 325 mg per day, is used routinely,
and ticlopidine, 250 mg twice a day, is also added.
The STARS (64) trial has now been completed and should
act as the reference document for adjunctive therapy. This
study enrolled 1,961 patients and randomized 1,652 patients in
a three-arm comparison-blinded evaluation of aspirin alone,
aspirin plus warfarin, and aspirin plus ticlopidine. The pre-
specified primary end point was a composite 30-day ischemic
end point that included death, Q-wave infarction, emergency
bypass surgery and subacute closure. To be eligible for ran-
domization, patients had to have no angiographic evidence of
thrombus at the end of the procedure, less than 10% residual
stenosis by visual estimate, no significant dissections following
stent implantation, TIMI-3 flow into a target vessel without
large side branch vessel occlusion and # two stents.
High pressures were used throughout the study with a mean
maximum pressure of 16.8 atm. The primary end point results
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confirmed the ISAR data. In the aspirin group, the composite
adverse end point occurred at 30 days in 3.6% of patients; in
the aspirin plus warfarin group, the end point at 30 days
occurred in 2.4%; and in the aspirin and ticlopidine group, the
adverse end point was seen in only 3 days (0.6%). In this trial,
ticlopidine was started the day of the procedure, usually in a
dose of 500 mg; it was then continued at 250 mg twice a day.
Current deployment techniques combined with aspirin and
ticlopidine have significantly decreased subacute closure rates.
When it occurs, however, it still results in a major increase in
severe complications (65,66). Hasdai et al. (65) reported on 29
patients with early coronary stent thrombosis over a 5-year
period. The mean time from implantation to stent thrombosis
was 6.1 6 5 days. Various techniques were used to treat the
stent thrombosis including angioplasty, angioplasty plus uroki-
nase and intracoronary urokinase. Of the patients treated with
a catheter-based approach, flow was restored without residual
thrombus in 11 patients (48%). Despite restoration of flow,
90% of the patients developed acute MI and there were two
deaths.
Although subacute closure rates are low with optimal stent
deployment, if the outcome of stent deployment is suboptimal,
subacute closure rates are increased. The STARS study in-
cluded a registry of 310 patients who did not meet entry criteria
because of suboptimal deployment. The combined end point of
death, emergency surgery, Q-wave infarction, and subacute
closure occurred in 7.8% of patients. Risks for subacute
closure included multiple stents, persistent thrombus and
decreased TIMI flow. In patients with suboptimal deployment,
low molecular weight heparin is currently being tested in a
randomized trial.
Ticlopidine has been an essential component to optimizing
initial outcome. Neutropenia occurs in 1% to 3% of patients,
but is rare prior to 14 days of treatment. Accordingly, an
increasing number of centers use ticlopidine 250 mg bid for
only 2 weeks (67). Ticlopidine may be started on the day of the
procedure in combination with the aspirin rather than two to
three days before stent implantation (54). An unanswered
question relates to the need for ticlopidine if IVUS is used to
guide deployment. In the MUSIC study (22), the subacute
closure rate was only 1.3% with monotherapy with ASA.
Recently, thrombotic thrombocytopenic purpura after ticlopi-
dine has received considerable attention because it markedly
increases morbidity and mortality (68).
Clopidogrel, similar to ticlopidine but with fewer side
effects, particularly less bone marrow suppression, has been
approved for use. Although it has not been tested with stent
implantation, it is now used relatively frequently. It may reduce
the adverse effects currently seen with ticlopidine without
increasing the incidence of subacute closure.
Summary
Stents should be deployed with a high pressure technique
utilizing $12–16 atm in combination with soluble aspirin
325 mg qd given indefinitely and ticlopidine 250 mg bid for 2 to
4 weeks. On the day of the procedure the ticlopidine can be
initiated with a dose of 500 mg. Clopidogrel may replace
ticlopidine in the future. Care should be taken to prevent or
treat suboptimal deployment because it increases the risk of
subacute closure.
IIb/IIIa Drugs
There is only limited data available on the use of IIb/IIIa
drugs (69–72). In three clinical trials with ReoPro™, the
EPILOG trial, the EPIC trial, and the CAPTURE trial, 529
patients received stents, the majority on a provisional basis.
The abciximab was given prospectively at the beginning of the
case independent of the subsequent decision to use a stent.
Administered after the development of complications, the
agent may not be as effective. A preliminary analysis in these
three trials indicates that the 30-day end point of death or MI
or urgent revascularization was reduced at 30 days. The
6-month outcome data are limited in these patients.
The use of combined stenting plus IIb/IIIa drugs (73)
increases the cost of the procedure and raises safety concerns.
The safety concerns appear to have been addressed in these
initial patients by weight-adjusting heparin and early sheath
removal and discontinuing heparin after the procedure. The
EPISTENT trial has now been reported, although full details
are not available. A total of 2,399 patients were randomized to
1) stent plus abciximab, 2) PTCA plus abciximab, or 3) stents
alone. Thirty-day events were markedly improved in the stent
plus abciximab mainly by a reduction in non-Q-wave infarction
reflected by creatine kinase, MB fraction (CK-MB) elevation.
Whether abciximab or a similar drug is indicated in all stent
patients is not yet clear.
Combined Therapies
Debulking followed by stenting to optimize initial and final
outcome has been tested with rotational atherectomy, direc-
tional coronary atherectomy, and also with transluminal ex-
traction atherectomy (TEC). A small number of reports ap-
pear to show some advantage. Multicenter studies are
currently in early stages of development and performance.
Stents and Radiation
There is intense interest in local radiation to prevent
restenosis—both with gamma as well as two with beta radia-
tion. One small randomized trial evaluated gamma radiation in
a high risk group of 55 patients with restenosis (74). Both
statistically and clinically significant improvement was shown in
angiographic, ultrasound and clinical end points. Currently, a
large number of trials are underway in a variety of patients and
lesion subsets, and with a variety of approaches.
Intravascular Ultrasounds (IVUS)
The tomographic orientation of IVUS enables visualization
of the full 360° circumference of the vessel wall and permits
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direct measurements of lumen dimensions including minimum
and maximum diameter and cross-sectional area (75–79).
Information from IVUS is additive to that obtained from
angiography. Because of the lattice characteristics of stents,
radiographic contrast material can surround the stent, produc-
ing an angiographic appearance of a large lumen even when
the stent struts are not in full contact with the vessel wall.
Several studies document the importance of full apposition of
the stent struts to the vessel wall. A large observational IVUS
study (76) following angiographically guided stent deployment
revealed an average residual plaque area of 51% comparing
minimum stent diameter to the reference segment diameter,
and incomplete wall apposition was frequent. In this cohort,
additional balloon inflations resulted in a final average residual
plaque area of 34%, even though the final angiographic
percentage stenosis was negative (20.7%). Employing ultra-
sound to guide deployment, these same authors reported a
subacute thrombosis rate of 0.3% using antiplatelet agents.
In the era of higher stent deployment pressures with aspirin
and ticlopidine therapy, the added value of IVUS is uncertain.
In the French registry study of 2,900 patients treated without
warfarin and without IVUS, subacute closure rate was 1.8%
(59). In the randomized STARS trial (64), which did not
require IVUS, a subacute closure rate in ideal implantation
outcome patients was 0.6%. At present, IVUS remains very
important in studying newer stent designs, and in evaluating
the results of higher risk procedures—those with multiple
stents, decreased TIMI flow and residual and marginal dissec-
tions. Whether IVUS-guided stent implantation will be able to
improve long-term outcome is currently being evaluated in
several randomized trials. The MUSIC trial (22) evaluated 161
patients in whom stent deployment was guided by ultrasound.
Optimal stent expansion was evaluated according to pre-
defined IVUS criteria; in 75% of patients, all three criteria
were met. In the remaining 25%, at least one IVUS criterion
was not met. In the group with optimal deployment, the
subacute closure rate was 1.3% even though monotherapy with
ASA was used in 86% of patients, angiographic restenosis was
documented in only 8%, and target vessel revascularization
was required in only 4.5% of patients. As previously men-
tioned, the CRUISE study (60) documented decreased TLR
when stent deployment was guided by ultrasound.
Summary
Intravascular ultrasound provides substantial information
as an adjunctive approach to guide stent placement. The
accumulating data indicate that it can be used to optimize early
and longer-term outcome in selected patients.
Physiologic Assessment
Assessment of the physiology of coronary stenosis has been
used to assay whether conventional PTCA has achieved a
satisfactory result (77,80,81). The DEBATE trial (58) suggests
that an ideal anatomic and physiologic result with conventional
PTCA results in an intermediate-term clinical result compara-
ble to stents. Widespread adoption of this approach may
decrease stent usage. Physiologic assessment can also be used
to assess the adequacy of stent implantation. Following satis-
factory stent implantation, the coronary flow reserve should be
normalized. The measurement of distal pressure under condi-
tions of maximal flow may also be effective in assessing
adequacy of deployment (81).
Cost Implications for Stenting
Evaluation of cost includes both direct and indirect costs of
the initial procedures and follow-up costs of medical care
(82–85). These evaluations must take into account the fact that
conventional PTCA with a bailout stent option (provisional
stenting) is improving long-term outcome. Routine stent im-
plantation is more expensive initially than conventional PTCA,
particularly when multiple stents are used. With the decreased
need for subsequent TLR in selected patients to treat resten-
osis, as well as decreased subsequent hospital admissions for
recurrent angina, longer-term costs of stenting may be more
equal to balloon angioplasty. New adjunctive therapy such as
IIb/IIIa drugs can change the cost/benefit ratio substantially.
Conclusions. Stent implantation improves both short- and
long-term outcome in selected patients. Multiple challenges
still remain, including diffuse instent restenosis, treatment of
bifurcation lesions, diffuse disease and small vessels. Resolu-
tion of these issues will further define the role of stenting in
optimizing percutaneous approaches to treatment of coronary
artery disease.
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